IDERA STARTS ONCOLOGY TRIAL OF HYB2055
Idera Pharmaceuticals has initiated a new Phase I/II clinical trial of HYB2055
in combination with the chemotherapy agents gemcitabine and carboplatin. The
trial is now open to patient enrollment at the Georgetown University Medical
Center in Washington, D.C. HYB2055 (also known as IMO-2055 or IMOxine) is Idera's
lead toll-like receptor 9 agonist for the treatment of cancer and is based on
Idera's proprietary immune modulatory oligonucleotide technology.
The trial is a two-phase, open-label, dose-escalation study of the safety and
efficacy of HYB2055 combined with a standard gemcitabine/carboplatin treatment
regimen. The primary endpoint of the Phase I portion of the trial is to establish
an appropriate HYB2055 dose in combination with a fixed dose of gemcitabine/carboplatin
in patients with solid tumors. In the Phase II portion of the study, the primary
endpoint is overall response rate and toxicity of the triplet combination in
previously untreated, advanced non-small cell lung cancer patients. HYB2055
will be administered by subcutaneous injection once per week. Intended Phase
I dose levels are 4, 12, and 36 mg per week.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May